BeiGene, Ltd. — FY2016 Form 10-K
Period: Fiscal year ended December 31, 2016; includes unaudited fourth-quarter results. The filing identifies the registrant as BeiGene, Ltd. (not “Beone Medicines Ltd.”). BeiGene is a clinical-stage oncology biopharmaceutical company with no approved products and no product-sales revenue. It reported one business segment.
Financial results and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue, entirely collaboration revenue | $1.1 million | $8.8 million |
| Research and development expense | $98.0 million | $58.3 million |
| General and administrative expense | $20.1 million | $7.3 million |
| Operating loss | $117.1 million | $56.7 million |
| Net loss | $119.2 million | $57.1 million |
| Basic and diluted loss per ordinary share | $0.30 | $0.52 |
| Cash used in operating activities | $89.5 million | $39.8 million |
Revenue was predominantly from Merck KGaA collaboration arrangements; there were no product sales. The revenue decline reflected lower BGB-283 collaboration revenue and no further BGB-290 revenue recognition after BeiGene repurchased ex-China rights in 2015. Profitability and product margins are not meaningful measures at this development stage.
- Q4 2016: Revenue was nil; operating loss was $37.3 million and net loss was $37.6 million, or $0.08 per share. Q4 2015 revenue was $4.7 million, operating loss $26.4 million, and net loss $27.3 million, or $0.23 per share.
- Year-end liquidity: Cash and cash equivalents were $87.5 million and short-term investments $280.7 million, totaling $368.2 million; working capital was $339.3 million. Short-term investments were primarily U.S. Treasury securities.
- Cash flow and funding: Investing activities used $221.8 million, mainly reflecting net purchases of securities and $23.5 million of property and equipment. Financing provided $380.9 million, including net proceeds of $366.7 million from the 2016 IPO and follow-on offering.
- Debt and obligations: Long-term bank debt was $17.3 million at 7%, secured by equipment and patent rights, repayable in 2018 and 2019. Operating lease commitments totaled $9.5 million and capital commitments $4.5 million at year-end. No off-balance-sheet arrangements were reported.
Material changes and business developments
- R&D spending increased about 68% year over year as clinical and preclinical programs advanced; G&A expense also rose substantially, including costs associated with hiring and being a public company.
- Operating cash use increased to $89.5 million from $39.8 million. The company completed its IPO and follow-on offering, strengthening liquidity, and converted preferred shares and its senior promissory note into ordinary shares in connection with the IPO.
- The four clinical-stage candidates were BGB-3111 (BTK), BGB-A317 (PD-1), BGB-290 (PARP), and BGB-283 (RAF). BGB-3111 entered pivotal studies, including a global Phase 3 Waldenström’s macroglobulinemia trial initiated in January 2017 and two China pivotal studies initiated in March 2017. Early-stage results across the pipeline are not equivalent to confirmatory pivotal evidence.
- After year-end, in March 2017, Merck KGaA declined its continuation option for BGB-283 outside China; BeiGene regained worldwide rights. Also after year-end, BeiGene agreed to establish a Guangzhou biologics manufacturing joint venture, with BeiGene’s subsidiary expected to hold 95% and make RMB200 million in cash contributions over three years.
Outlook, risks, and unusual items
- Management expects significant operating losses and negative cash flows for the foreseeable future, with spending rising as trials, manufacturing investment, and public-company costs expand. Management estimated year-end cash, equivalents, and short-term investments would fund operations and capital needs for at least 15 months under its current plan; another discussion in the filing says at least 12 months.
- Key uncertainties include trial success, enrollment and safety, regulatory approval in the U.S., China and other markets, manufacturing scale-up, commercialization capability, reimbursement, and competition. China’s Category 1 pathway may offer advantages, but its implementation and the company’s ability to retain the designation are uncertain.
- BeiGene depends on collaboration revenue, which was concentrated in one customer, Merck KGaA, in the periods presented. The BGB-283 rights change alters the collaboration outlook; BGB-290 remains subject to China-specific rights and option provisions described in the filing.
- Other material risks include potential third-party patent claims involving BGB-A317, BGB-3111, and BGB-290; reliance on CROs and external manufacturers; foreign-exchange and China regulatory risks; and the need for additional financing if development needs exceed available resources.
- The company reported effective disclosure controls and internal control over financial reporting at December 31, 2016, and said a previously identified material weakness related to financial-reporting staffing had been remediated. The auditor did not provide an ICFR attestation because BeiGene was an emerging growth company.
- Unusual items included a $1.4 million loss on sale of available-for-sale securities and a $1.5 million loss from fair-value changes in financial instruments in 2016. A $2.9 million gain on debt extinguishment was recorded in 2014, not 2016.
Most important facts for investors to verify
- Confirm the runway assumptions and reconcile the filing’s “at least 12 months” and “at least 15 months” liquidity statements.
- Track cash burn against the $368.2 million of cash and short-term investments, planned trial expansion, and manufacturing commitments.
- Assess pivotal-trial enrollment, endpoints, safety, and results for BGB-3111; treat early response data and cross-trial comparisons cautiously.
- Verify the consequences of the BGB-283 rights reversion and the terms, funding, and execution of the Guangzhou manufacturing joint venture.
- Review ongoing patent exposure, especially for the PD-1, BTK, and PARP programs, and monitor collaboration-related rights and potential milestones.
- Monitor revenue concentration and the timing of any future collaboration payments, since the company had no product-sales revenue.